Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas - INSTAL-101

NCT04144140 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT04144140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04144140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas - INSTAL-101
Lead sponsor
Eisai Inc.
Phase
Phase 1
Overall status
Terminated
Start date
February 24, 2020
Completion date
July 26, 2022
Enrollment
24 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, lymphoma